Corindus Vascular Robotics (CVRS) Says Delray Beach Medical Center Performs First Robotic-Assisted Peripheral Vascular Intervention Using its CorPath GRX System

February 22, 2018 8:55 AM EST
Get Alerts CVRS Hot Sheet
Price: $4.27 --0%

Overall Analyst Rating:
    BUY (= Flat)

Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Corindus Vascular Robotics, Inc. (NYSE: CVRS), a leading developer of precision vascular robotics, announced today the successful completion of the first robotic-assisted peripheral vascular intervention procedure using the recently FDA-cleared CorPath GRX System. The procedure was performed by Joseph Ricotta, M.D., Medical Director of Vascular Surgery and Endovascular Therapy, Tenet Healthcare, Professor of Surgery, Charles E Schmidt College of Medicine, FAU. CorPath GRX is the first and only FDA-cleared medical device to bring robotic-assisted precision to both percutaneous coronary and percutaneous vascular interventional procedures.

"I am honored to have performed the first peripheral vascular procedure with CorPath GRX. GRX enables me to combine enhanced visualization of the X-ray images with the precision of robotics to transform the way we perform peripheral vascular procedures and should ultimately improve patient care," said Dr. Ricotta. "I look forward to partnering with Corindus to pioneer robotics for endovascular therapies, providing benefits to both healthcare professionals and patients."

Peripheral artery disease (PAD) is a disease of blood vessels outside the heart that commonly affects arteries carrying blood to the lower extremities. It is estimated that 8.5 million people in the United States are living with PAD.1

"We are privileged to partner with Dr. Ricotta as the first physician in the U.S. to perform peripheral vascular interventions with the CorPath GRX System following FDA clearance for this indication," said Mark Toland, President and Chief Executive Officer of Corindus. "The adoption of the CorPath GRX System at Delray Beach Medical Center emphasizes their continuous commitment to delivering state of the art technology to their patients and clinical community."

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and percutaneous vascular procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Management Comments

Related Entities

FDA